Navigation Links
ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert;
Date:5/4/2009

= 520) were given a general dry eye evaluation, screened by slit-lamp biomicroscopy and best corrected visual acuity, and were required to fill out a questionnaire that included the ocular surface disease index (OSDI), a validated measure of quality of life. Patients were trained on the proper insertion and use of the insert. Patients were contacted by telephone on Day 3 of the study for follow up and reinstruction. At visit 2 (Week 4), patients were given a clinical evaluation and required to complete a second evaluation. Answers provided on questionnaires (scored on Likert-type scales) were used to determine changes in patient-reported outcomes such as symptoms and quality of life.

About Lacrisert

Lacrisert has been FDA-approved for use in patients with moderate to severe dry eye and available by prescription for more than two decades. Unlike artificial tear substitutes that have a residence time measured in minutes, Lacrisert provides continual lubrication and protection to the surface of the eye for all-day relief. Lacrisert acts to stabilize and thicken the pre-corneal tear film and prolong the tear film breakup time, which is usually accelerated in patients with dry eye states. Information and educational video content are available at www.Lacrisert.com.

Most adverse reactions with Lacrisert were mild and transient and included transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids and hyperemia. Lacrisert should not be used by patients who are hypersensitive to hydroxypropyl cellulose. If improperly placed, Lacrisert may result in corneal abrasion.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for un
'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PSA Screening Cuts Deaths by 20%, Says Worlds Largest Prostate Cancer Study
2. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
3. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
4. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
5. CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
6. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
7. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
8. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
9. Velos Set to Clear 50 Percent Market Penetration of Large U.S. Clinical Research Sites by Year End
10. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
11. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015   Ivenix Inc. , a medical ... closed on a $42M round of equity financing ... Partners, CICA, Inc., Easterly Capital, Fidelity Biosciences, and ... This financing will support the company,s efforts to ... LLC acted as the exclusive placement agent for ...
(Date:9/1/2015)... California , September 1, 2015 ... is segmented on the basis of sectors, products ... chronic diseases globally coupled with the increasing demand ... diseases are expected to propel the growth for ... manage biological information efficiently is known as bioinformatics. ...
(Date:9/1/2015)... Sept. 1, 2015 Within just two ... Group has rapidly reached 3,000 employees worldwide. This ... in the injectable drug delivery market and SHL,s ... global leader in the design and manufacturing of ... designs, robust manufacturing capabilities, a lean supply chain, ...
Breaking Medicine Technology:Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4SHL Group Reaches Major Milestone of 3000 Employees 2
... WIRE)--Jun 4, 2007 - Cytogen Corporation,(NASDAQ: CYTO) ... QUADRAMET (samarium Sm-153 lexidronam injection),can be safely ... also,receiving the chemotherapy docetaxel (Taxotere(R), Sanofi-Aventis).,Clinical data ... for the treatment of prostate cancer in ...
... 2007 /PRNewswire-FirstCall/ -- VION,PHARMACEUTICALS, INC. announced that it ... the 43rd Annual Meeting of The American,Society of ... (VNP40101M) as a single agent in a Phase ... cell lung cancer. , The Phase II trial ...
Cached Medicine Technology:New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 2New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 3New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 5New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 6New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 7Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 2Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 3Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 4
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... PAYROLL FITNESS" and will provide two days of payroll education covering legislative updates, ... technology changes. The speakers, which include representatives from Ceridian, Ultimate Software, the American ...
(Date:9/2/2015)... ... September 02, 2015 , ... This Fall, as ... (BCAM), Bright Pink, a national non-profit focused on the prevention and early detection ... a campaign to educate women to be breast and ovarian self-aware and celebrate ...
(Date:9/1/2015)... ... ... men, the first thing they notice when they go to button their white collar shirt ... with a collar that doesn’t close against the skin, creating a sloppy look. Or men ... because it’s uncomfortable. Now men in suits will be able to do something about ...
(Date:9/1/2015)... ... September 01, 2015 , ... Earth Brands, ( http://www.earthbrands.com ... collection. Every customer who buys an Earth Brand shoe will be given an ... Trees for the Future, a nonprofit dedicated to planting more trees. Earth Brands ...
(Date:9/1/2015)... San Diego, CA (PRWEB) , ... September 01, 2015 , ... ... with Bellus Academy will present “The Beauty Behind the Fashion” on Thursday, Oct. ... San Diego® (FWSD), will shine the spotlight on the collaboration between fashion and professional ...
Breaking Medicine News(10 mins):Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3
... helps reduce the risk of reactivating the hepatitis B ... for breast cancer.An estimated 12 percent // of breast ... patients are at risk of developing HBV reactivation during ... degrees of liver damage that may lead to death. ...
... Most men with prostate cancer would rather find out sooner ... tested for prostate cancer using the prostate-specific antigen test. But since ... // for doctors to know what a high reading is and ... with higher levels have to undergo repeated biopsies to determine whether ...
... disease is a genetic disease that occurs predominantly in people ... from blood vessels being blocked by red blood cells // ... High blood pressure in the lungs is known as pulmonary ... pressure measured by a cuff on your arm. Instead, pulmonary ...
... study sheds light on the theory that aging is associated ... suggest the gene responsible for shortening the ends of chromosomes ... measured the length of the end of the chromosomes, known ... random sample of families living in northern Belgium. Telomere length ...
... the University of Chicago ( an evolution specialist ), ... The consortium's research, genetically fingerprinted virus samples from several ... Kong.// ,The work provides more evidence that SARS ... suggests, that prompt control of new cases is crucial, ...
... for kids in the United Kingdom, finds a new ... preschoolers. ,The study involved 78 children who were 3 ... their total energy expenditure, along with their amount of ... were spending only about 20 to 25 minutes a ...
Cached Medicine News:Health News:Reducing The Risk Of Death In Sickle Cell Disease 2Health News:Scientists Have Traced How The SARS Virus evolved 2
... Faster speeds, highest precision, more user-friendliness and ... this is the definition of the Mastercycler ... nucleic acid research has been developing dynamically. ... of PCR Systems. To keep pace ...
... Thermal Cycler is one of the smallest ... Benefits include: Fast ramping, low cost, ... and program naming, Ready-to-go templates, interchangeable blocks. ... Biology and Diagnostic laboratories and is suitable ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 16x0.5ml tubes...
... The DNA Engine instrument is the ... uniformity and swappable blocks ensure consistent results, ... more than just a cycler, it's a ... research needs evolve. DNA Engine thermal cycler ...
Medicine Products: